[Use of triptanes according to indications. Risk of infarct is not increased].
D002544:Cerebral Infarction / Q000139:chemically induced*; D002986:Clinical Trials as Topic; D003326:Coronary Circulation / Q000187:drug effects; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000009:adverse effects*; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D008881:Migraine Disorders / Q000188:drug therapy*; D009203:Myocardial Infarction / Q000139:chemically induced*; D011759:Pyrrolidines / Q000008:administration & dosage / Q000009:adverse effects*; D012306:Risk; D017366:Serotonin Receptor Agonists / Q000008:administration & dosage / Q000009:adverse effects*; D018170:Sumatriptan / Q000008:administration & dosage / Q000009:adverse effects*; D014363:Tryptamines; D014661:Vasoconstriction / Q000187:drug effects; D014662:Vasoconstrictor Agents / Q000008:administration & dosage / Q000009:adverse effects*
D007211:Indoles; D011759:Pyrrolidines; D017366:Serotonin Receptor Agonists; D014363:Tryptamines; D014662:Vasoconstrictor Agents; C115647:eletriptan; D018170:Sumatriptan